Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Genedrive Share News (GDR)
GDR Share
Price
GDR Share
News
GDR Share
Chat15
GDR Share
Trades37
GDR
Live RNS
GDR Share
Charts
GDR Level 2
Console
GDR Live
Share Price
GDR Broker
Ratings
GDR Directors
Deals
GDR Financial
Diary
GDR
Fundamentals
GDR Short
Positions
GDR
Media
GDR Company
Research
GDR Company
Timeline
Share Price Information for Genedrive (GDR)
Last checked at -
Last checked at 
Intraday Genedrive Share Chart
Genedrive News
Genedrive collects £0.76m R&D tax credit
(Sharecast News) - Genedrive said on Friday that it had received a research and development tax credit refund of about £0.76m from HMRC.
Genedrive chair to step down; adds shareholder David Nugent to board
(Alliance News) - Genedrive PLC on Tuesday said it has appointed a major shareholder to its board, as it reported that Chair Ian Gilham plans to step ...
Sussex NHS trust moves to routine use of Genedrive test
(Sharecast News) - Genedrive said on Tuesday that the University Hospitals Sussex NHS Foundation Trust had moved its MT-RNR1 test into routine clinica...
TRADING UPDATES: Ajax in exclusive talks with China buyer for Eureka
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...
Genedrive hopeful of product adoption and regulatory clearances
(Alliance News) - Genedrive PLC on Monday said it is "well positioned" to build on the progress achieved during 2025.
TRADING UPDATES: Genedrive raises extra funds through subscription
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Genedrive narrows loss as revenue nearly doubles on MT-RNR1 test
(Alliance News) - Genedrive PLC on Friday reported a narrowed full-year loss as its net finance costs fell and revenue almost doubled from routine use...
Follow the stocks
